Head-to-head comparison
Rebody Health vs Synergy Rx
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Rebody Health (rebodyhealth.com), operated by Compound Technologies Inc., is a transparent-pricing GLP-1 and wellness telehealth service that publishes prices up front.
From $200/mo (lowest dose rung) sema · From $250/mo (lowest dose rung) tirz · Verified July 2026
Marked down on: Individual compounding pharmacies are not named on the marketing site
Desk Score
Brand Wegovy, Ozempic or Mounjaro when clinically appropriate, with unlimited round-the-clock clinical contact.
From $199 sema · From $349 tirz · Verified August 2026
Marked down on: Prints only "Starting at" figures — $199 semaglutide, $349 tirzepatide — with no billing cycle, term or dose, and its FAQ says the price is provided after the consultation
Rebody Health takes this head-to-head with the higher Desk Score, 79/100 (C+) against 72/100 (C) for Synergy Rx. Synergy Rx still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Rebody Health
79/100
C+
Synergy Rx
72/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Rebody Health | Synergy Rx |
|---|---|---|
| Semaglutide | From $200/molowest dose rung$200/mo (starting dose, compounded) | From $199From $199 (the Weight Loss tab on synergyrx.co/products prints "Starting at $199" with no term, dose or billing cycle; the FAQ says the price is given after the consultation; compounded injectable) |
| Tirzepatide | From $250/molowest dose rung$250/mo (starting dose, compounded) | From $349From $349 (the Weight Loss tab on synergyrx.co/products prints "Starting at $349" with no term, dose or billing cycle; the FAQ says the price is given after the consultation; compounded injectable) |
| Coverage | 47 states | All 50 states per its FAQ (its terms say to email support for the current list) |
| Brand-name | Yes | Yes |
| Oral option | Yes | Yes |
| Best for | Shoppers who want transparent, dose-based GLP-1 pricing with oral, injectable, or brand-name options. | People who want a brand-name lane and as much clinician access as possible, and will get pricing by inquiry. |
| Desk Score | 79/100C+ | 72/100C |
The verdict
Desk pick — Rebody HealthRebody Health takes this head-to-head with the higher Desk Score, 79/100 (C+) against 72/100 (C) for Synergy Rx. Synergy Rx still holds its ground where its strengths line up with yours.
Choose Rebody Health if…
Shoppers who want transparent, dose-based GLP-1 pricing with oral, injectable, or brand-name options.
From $200/mo (lowest dose rung) sema · From $250/mo (lowest dose rung) tirz · 47 states
Choose Synergy Rx if…
People who want a brand-name lane and as much clinician access as possible, and will get pricing by inquiry.
From $199 sema · From $349 tirz · All 50 states per its FAQ (its terms say to email support for the current list)
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Rebody Health · Synergy Rx.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- CoreAge Rx vs Rebody Health
- CoreAge Rx vs Synergy Rx
- Rebody Health vs Shed
- Shed vs Synergy Rx
- Rebody Health vs Vaylen
- Synergy Rx vs Vaylen
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.